NantOmics Announces Study Showing Signature Analysis That Reveals Three Distinct Classifications of Skin Cancer Known as Seba...
May 21 2018 - 12:30PM
Business Wire
Research published on May 14 in the
peer-reviewed journal Nature Communications shows for the first
time three distinct classifications of sebaceous carcinoma, a rare
and sometimes deadly form of skin cancer.
NantOmics, LLC, the leader in molecular analyses and a member of
the NantWorks ecosystem of companies, announced today the
publication of peer-reviewed research defining for the first time
three distinct classifications of sebaceous carcinoma, a rare and
sometimes deadly former of skin cancer.
A study published on May 14 in the journal Nature Communications
shows that a signature analysis reveals three clinically distinct
classes of sebaceous carcinoma. The research offers fresh insights
into how to treat the disease and adds more data to the concept
that different mutational processes drive cancers that originate in
the same location but are clinically distinct.
Using the technology that drives NantHealth, Inc.’s (NASDAQ: NH)
GPS Cancer® platform, NantOmics scientists performed tumor-normal
DNA sequencing and RNA sequencing on tissue samples from 32
patients with sebaceous carcinoma, revealing that the cell of
origin and mutation patterns defined three clinically distinct
classes. These explain both cancer ontogeny and clinical
course.
“This is the first time that we have been able to define
sebaceous carcinoma into distinct molecular classifications with
defined mutational signature profiles,” said Dr. Shahrooz
Rabizadeh, Chief Scientific Officer at NantOmics. “We believe that
our findings and the classifications have significant implications
on patient treatment.”
Dr. Patrick Soon-Shiong, CEO and founder of NantOmics, said the
research reiterated the importance of no longer treating cancer by
anatomy, but based on biology.
“This research has helped to decode signatures that are based on
the disease’s molecular profile,” Soon-Shiong said. “Beyond
treatment implications, this shows the absolute importance of
looking at cancer treatment from a biological perspective.”
Nature Communications is a peer-reviewed, open-access journal
that publishes research on all areas of natural sciences. Papers
published by the journal are considered to represent important
advances in their fields of research.
Other highlights from the paper:
- A UV-damage signature classification
predominates in ten of the 32 samples.
- Nine of the samples are classified by
microsatellite instability (MSI) profiles, which has been shown to
be responsive to and is approved for pembrolizumab (Keytruda®)
use.
- The third classification,
pauci-mutational sebaceous carcinoma has a more varied signature,
but half of which shared a similar mutation pattern in ZNF750
transcription factor in this study.
- Neoepitope analysis identified a subset
of patients with highly clonal mutation burden that may be most
responsive to immunotherapy, and may potentially be strong
candidates for treatment with neoepitope vaccines.
About NantOmics, LLC
NantOmics, a member of the NantWorks ecosystem of companies,
delivers molecular analysis capabilities with the intent of
providing actionable intelligence and molecularly driven decision
support for cancer patients and their providers at the point of
care. NantOmics is the first molecular testing company to pioneer
an integrated approach to unearthing the genomic and proteomic
variances that initiate and drive cancer, by analyzing both normal
and tumor cells from the same patient and following identified
variances through from DNA to RNA to protein to drug. NantOmics has
a highly scalable cloud-based infrastructure capable of storing and
processing thousands of genomes a day, computing genomic variances
in near real-time, and correlating proteomic pathway analysis with
quantitative multi-plexed protein expression analysis from the same
micro-dissected tumor sample used for genomic analysis. For more
information please visit www.nantomics.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of
companies, is a next-generation, evidence-based, personalized
healthcare company enabling improved patient outcomes and more
effective treatment decisions for critical illnesses. NantHealth's
unique systems-based approach to personalized healthcare applies
novel diagnostics tailored to the specific molecular profiles of
patient tissue and integrates this molecular data in a clinical
setting with large-scale, real-time biometric signal and phenotypic
data to track patient outcomes and deliver precision medicine. For
nearly a decade, NantHealth has developed an adaptive learning
system that integrates our unique molecular profiling solution,
software and hardware. Our system infrastructure collects, indexes,
analyzes and interprets billions of molecular, clinical,
operational and financial data points derived from novel and
traditional sources to continuously improve decision-making and
optimize our clinical pathways and decision algorithms over time.
For more information please
visit http://www.nanthealth.com/.
About GPS Cancer®
GPS Cancer® is a unique, comprehensive test available through
NantHealth. GPS Cancer integrates tumor/normal DNA and RNA
sequencing, with enhanced expression analysis and bioinformatics of
complex biologic pathway systems, providing oncologists with a
comprehensive molecular profile of a patient’s cancer to inform
personalized treatment strategies. GPS Cancer testing is conducted
in CLIA-certified and CAP-accredited laboratories. For more
information, visit www.gpscancer.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180521005846/en/
NANT MEDIA CONTACTJen
Hodsonjhodson@nantworks.com562-397-3639orHenry
Jacksoncj@nantworks.com310-486-8908
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jun 2024 to Jul 2024
NantHealth (NASDAQ:NH)
Historical Stock Chart
From Jul 2023 to Jul 2024